DRI Healthcare Trust · TSX:DHT.U

DRI Healthcare Trust — Investor Presentation (May 2023)

30 slides from DRI Healthcare Trust's investor presentation, May 2023

  1. Slide 1: Advancing Science in the Fast-Growing Pharmaceutical and Biotechnology Sector

    ADVANCING SCIENCE in the Fast-Growing Pharmaceutical and Biotechnology Sector May 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by DRI Healthcare Trust (the “Trust”). The Trust is an unincorporated open-ended fund trust governed by the laws of the Province of Ontario, Canada and is externally managed by DRI Capital Inc. (“DRI Capital” or the “Manager” and together with the Trust

  3. Slide 3: Low risk exposure to rapid biopharma growth

    Low risk exposure to rapid biopharma growth For the year ended December 31, 2022 34-year1 Neurology 17% Oncology 24% $93M History Total Income 23 $2.5B+ Other 7% Royalty assets2 $82M Capital deployed 19 Adjusted EBITDA3 Products 71 Dermatology 6% 86% Royalty acquisitions $1B+ Respiratory 9% Adjusted

  4. Slide 4: Our competitive advantages

    Our competitive advantages 1 Seasoned 2 Disciplined 3 Proactive 4 Strong team capital sourcing execution allocation of specialized based on robust proprietary fundamental investment investment criteria database tracking ground-up diligence professionals with that has resulted in royalties on more on

  5. Slide 5: Track record of delivering growth and value

    Track record of delivering growth and value Drug Royalty I Drug Royalty II Drug Royalty III DHT 2006 – 20081 2009 – 20131 2013 – 20181 2021 - present 19 New Royalties 27 New Royalties 15 New Royalties 10 New Royalties & 1 Loan valued at valued at valued at valued at up to $645M $730M2 $586M $561M3 I

  6. Slide 6: Delivering on our long-term strategy

    Delivering on our long-term strategy At IPO Today 2025 target1 $485 million deployed to date Revised deployment target of Capital deployment $650 – 750 million over 5 years + $850 – 900 million $76 million in milestones and options Flat to slightly growing cash Sustainable cash Declining cash curve

  7. Slide 7: Current deployment exceeds targets

    Current deployment exceeds targets ($M) 8-Mar-232 700 Additional milestones + options Milestone Actual deployment payment 600 25-Jan-23 25-Nov-22 500 30-Sep-22 400 9-Sep-22 300 30-Sep-21 20-Jul-221 28-Feb-22 200 25-Aug-21 100 0 Feb-21 May-21 Aug-21 Nov-21 Feb-22 May-22 Aug-22 Nov-22 Feb-23 Deploymen

  8. Slide 8: Industry R&D spending is propelling innovation

    Industry R&D spending is propelling innovation Worldwide Total Pharmaceutical R&D Spend ($B)1 Worldwide Medicine Spending ($B)2 Total R&D spend 2022-2028 2027 $1.8 trillion $1.9 trillion 300 280 1800 260 1600 240 1400 220 1200 200 1000 180 800 160 600 140 400 120 200 100 0 2023E 2024E 2025E 2026E 20

  9. Slide 9: R&D spending has resulted in many innovative products

    R&D spending has resulted in many innovative products Novel Drug Approvals by the FDA1 60 50 40 30 20 10 0 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023E FDA approval of novel drugs opens the door to abundant royalty acquisition opportunities 1. Source: Historic: FDA.gov, 2023 Forecast: Eva

  10. Slide 10: Royalty transaction activity is expanding with strong industry tailwinds

    Royalty transaction activity is expanding with strong industry tailwinds Trailing three-year average number of transactions1 Trailing three-year average value of transactions ($B)1 40 7 35 6 30 5 25 4 20 3 15 2 10 5 1 0 0 2017 2018 2019 2020 2021 2022 2017 2018 2019 2020 2021 2022 Aggregate royalty

  11. Slide 11: State of the biotech market

    State of the biotech market Biotech IPOs1 Biotech Equities Performance2 16 120 140 130 14 100 120 12.7% 12 110 80 Total Proceeds ($B) 10 100 -8.4% Number of IPOs 90 8 60 80 6 70 40 -43.1% 4 60 20 50 2 40 Jan-21 Feb-21 Jan-22 Feb-22 Jan-23 Feb-23 Mar-21 Nov-21 Dec-21 Apr-21 Jun-21 Jul-21 Mar-22 Nov-2

  12. Slide 12: Biotechs' limited cash reserves

    Biotechs’ limited cash reserves Cash Runway for Unprofitable Biotechs (months) Q4 2022 Q1 2023 (estimate) <12 <12 ≥24 ≥ 24 12-18 12-18 18-24 18-24 ≥24 months = 40% ≥ 24 months = 35% <12 months = 20% <12 months = 30% 65% of unprofitable NASDAQ-listed biotechs are estimated to have <2 years of cash Ti

  13. Slide 13: Creating win-win deals for multiple counterparties

    Creating win-win deals for multiple counterparties Monetize long-term royalties in Provide royalty financing flexible, tax advantaged deals to fund capital projects Research Inventors institutions Flexible approach – Existing royalties – Synthetic royalties – Launch & development capital Monetize ex

  14. Slide 14: Proven track record of closing accretive transactions

    Proven track record of closing accretive transactions Investment Thesis Transaction Size High-quality oncology product with strong $116.5 million + growth potential $18.5 million potential milestone Dermatology product with existing $50.5 million commercial track record Hematology and ophthalmology

  15. Slide 15: Sustainable and efficient business model focused on cashflow

    Sustainable and efficient business model focused on cashflow % Sales of leading therapies and/or interest payments Sourcing, research New asset Total Cash & deal execution acquisitions Receipts1 Cash for Adjusted redeployment EBITDA1 Cash distributions Business model allows for continuous compoundin

  16. Slide 16: Robust diversified portfolio

    Robust diversified portfolio By Therapeutic Area1 By Product1 Other Zytiga Rydapt 6% Natpara 4% 2% Dermatology 4% 6% Eylea Lysosomal Storage 4% Omidria Disorder Ophthalmology 24% 6% 32% Empaveli/Syfovre 5% Xenpozyme Respiratory 6% 9% Oracea 6% Spinraza Zejula 17% Neurology 7% 17% Oncology 24% Xolair

  17. Slide 17: 2022 financial highlights

    2022 financial highlights $96.2 million $93.0 million $82.4 million Total Cash Receipts1 Total Income Adjusted EBITDA1 $1.87 $0.30 86% Declared Cash Distributions Adjusted Cash Earnings per Adjusted EBITDA Margin1 per Unit Unit1 1. Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. Adjus

  18. Slide 18: Strong cash generation

    Strong cash generation Adjusted EBITDA for the Year Ended December 31, 2022 ($M)1 $3.7 $96.2 $87.3 $5.7 $93.0 ($0.5) ($7.3) ($6.5) $82.4 Adjusted EBITDA Margin1 86% Adjusted Cash Earnings per Unit4 Royalty Income Interest Income Total Income on Loan Net Change in Royalties Non-Cash Royalty Income To

  19. Slide 19: Deal structure case study: CTI Biopharma / Vonjo

    Deal structure case study: CTI Biopharma / Vonjo - Funding for Vonjo launch preparation Pre-approval $50 million secured loan - Secured loan provides downside protection if approval not granted - Funding for Vonjo launch $60 million tiered royalty - Sliding royalty rates as annual sales increase Upo

  20. Slide 20: Oracea royalty transaction

    Oracea royalty transaction 1 TRANSACTION HIGHLIGHTS STRONG GROWTH POTENTIAL Immediate accretive value with $50.5 million purchase price for substantial royalty receipts netted royalties on worldwide sales out of purchase price Among leading treatment Two additional royalty interests options for mana

  21. Slide 21: Empaveli royalty transaction

    Empaveli royalty transaction 1 TRANSACTION HIGHLIGHTS STRONG GROWTH POTENTIAL Represents a significant advancement in the standard of $28.2 million purchase price1 care for Paroxysmal Nocturnal Hemoglobinuria <1% royalty on worldwide net Approved as the first and only sales up to $500 million per ap

  22. Slide 22: Zejula royalty transaction

    Zejula royalty transaction TRANSACTION HIGHLIGHTS STRONG GROWTH POTENTIAL 1 $10 million milestone payment if Zejula is approved by FDA for the $35 million up front purchase price treatment of endometrial cancer by December 21, 2025 In development for metastatic castrate sensitive and resistant 0.5%

  23. Slide 23: Omidria royalty transaction

    Omidria royalty transaction TRANSACTION HIGHLIGHTS STRUCTURED GROWTH 1 Annual Royalty Receipt Caps ($M) $125 million up front purchase $30 price, subject to annual cash receipt 26.25 27.50 caps 25.00 25.00 25.00 25.00 $25 20.00 $20 Approved for intracameral use during cataract surgery or $15 intraoc

  24. Slide 24: Xenpozyme royalty transaction

    Xenpozyme royalty transaction TRANSACTION HIGHLIGHTS STRONG GROWTH POTENTIAL 1 $26.5 million in potential $30 million up front purchase price milestone payments based on cumulative royalties received First and only approved product for Approximately 1% royalty on the treatment of Acid worldwide sale

  25. Slide 25: Tzield royalty transactions

    Tzield royalty transactions ACQUISITION FROM MACROGENICS SALE TO SANOFI 1 $100 million up front purchase price for a Sanofi announced agreement to acquire single digit royalty on Provention Bio’s Provention Bio days after DRI Healthcare’s worldwide net sales acquisition of the royalty Up to a $50 mi

  26. Slide 26: Portfolio performance

    Portfolio performance ($ thousands) Asset Primary Marketer(s) Therapeutic Area Total Cash Royalty Receipts1,2 Net Book Value FY 2022 12/31/22 Hematology / Ophthalmology 269 23,437 Ophthalmology 11,280 23,041 Vaccine 2,952 2,096 Endocrinology 2,625 19,457 Ophthalmology 1,670 121,782 Dermatology 7,662

  27. Slide 27: Growth opportunities from existing assets

    Growth opportunities from existing assets1 Phase 1 Phase 2 Phase 3 Phase 4 RESPOND: Spinraza in patients who had received Zolgensma Spinraza ASCEND: Higher dose Spinraza in patients who had received Evrysdi DEVOTE: Higher dose Spinraza Vonjo PACIFICA: Confirmatory trial in Myelofibrosis Xolair OUTMA

  28. Slide 28: Committed to best practices in ESG

    Committed to best practices in ESG Environmental Social Governance Building a platform for sustainability Accountability and integrity as core Valuing diversity and community values support • Review of sustainability practices of our • Highly diverse and inclusive team • Best practice governance pol

  29. Slide 29: Our key priorities

    Our key priorities Invest in our people and build the industry leading royalty investment team People Execute on strong pipeline and operate at Execution peak performance in all aspects of our business Results Focus on long-term, sustainable growth generating strong unitholder returns 29

  30. Slide 30: Contact Us

    Contact Us Dave Levine [email protected]

DRI Healthcare Trust — Investor Presentation (May 2023) on 6ix